Labcorp’s Q3 earnings call: our top 5 analyst questions

Labcorp's third quarter results were marked by strong growth in specialty testing and continued expansion in biopharma laboratory services, leading to performance that exceeded Wall Street's expectations. Management highlighted disciplined execution and volume growth across diagnostics as key contributors. CEO Adam Schechter attributed the quarter's momentum to "continued strength in central laboratories and specialty testing," underscoring the value of Labcorp's clinical partnerships and recent advancements in areas such as oncology and neurology.

Is now the time to buy LH? Find out in our full research report (it's free).

Labcorp (LH) Q3 2026 highlights:

• Revenue$3.81 billion vs S&P analysts' estimates of $3.76 billion (6.9% year-on-year growth, 1.2% beat)

• Adjusted EPS$4.78 vs S&P analysts' estimates of $4.64 (2.9% beat)

• Revenue guidanceThe company slightly lifted its revenue guidance for the full year to $14.83 billion at the midpoint from $14.77 billion

• Adjusted EPS guidanceManagement slightly raised its full-year adjusted EPS guidance to $18.50 at the midpoint

• Operating margin10.6%, in line with the same quarter last year

• Organic revenuerose 5.5% year on year (beat)

• Market capitalization$29.89 billion

While we enjoy listening to the management's commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our top 5 analyst questions from Labcorp's Q3 earnings call

• Erin Wilson Wright (Morgan Stanley)questioned how Labcorp plans to maintain margin expansion amid PAMA-related pressures and recent acquisitions. CEO Adam Schechter explained that multiple levers—including diagnostics, biopharma, Launchpad savings, and business development—will be used to offset the impact, but acknowledged the challenge in the implementation year.

• Lisa Gill (JPMorgan)sought clarity on the margin trajectory of new acquisitions and the strength of the M&A pipeline. Schechter emphasized strong pipeline visibility and noted that each deal is expected to be accretive, with integration plans tailored to maximize margin improvement over time.

• Ann Hynes (Mizuho)asked about the effect of new cardiovascular screening recommendations on women's health testing volumes. Schechter noted that guideline changes typically lead to increased test prescriptions and insurance coverage, though the impact is gradual and challenging to quantify immediately.

• Eric Coldwell (Baird)pressed for details on the expected accretion and margin structure of the BioReference deal. Schechter and CFO Wang explained that operational synergies—such as consolidating service centers and leveraging procurement scale—support the accretion forecast and margin improvement relative to the acquired business's standalone performance.

• Luke Sergott (Barclays)inquired about demand trends and capacity in biopharma services. Schechter highlighted robust growth in central laboratory business, driven by pharmaceutical demand in oncology and cardiometabolic trials, and stated that Labcorp has ample capacity to accommodate future growth.